Suppr超能文献

局部晚期不可切除的肝内和肝外胆管癌的放射剂量递增

Radiation dose escalation for locally advanced unresectable intrahepatic and extrahepatic cholangiocarcinoma.

作者信息

Avila Santiago, Smani Danyal A, Koay Eugene J

机构信息

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Chin Clin Oncol. 2020 Feb;9(1):10. doi: 10.21037/cco.2019.12.05. Epub 2019 Dec 19.

Abstract

Intrahepatic cholangiocarcinoma (IHCC) and extrahepatic cholangiocarcinoma (EHCC) remain challenging diseases to treat. The majority of patients present with advanced disease, and the tumors often cause life-threatening biliary obstruction and vascular compromise of the liver. Local control (LC) of these tumors has the potential to prolong life for patients. While escalated-dose radiation therapy (EDRT) has been demonstrated to be an effective, safe option to achieve LC of IHCC, data for EHCC suggest that EDRT with current techniques has limitations, often due to dose-limiting bowel structures in close proximity to the extrahepatic biliary system. Here we review the results of EDRT for IHCC and EHCC and point to potential directions to combine radiotherapy with novel agents. The molecular characterization of cholangiocarcinoma has particularly opened new avenues for clinical investigations of targeted therapies with EDRT and may point to ways to achieve both systemic and LC benefits for patients.

摘要

肝内胆管癌(IHCC)和肝外胆管癌(EHCC)仍然是治疗上具有挑战性的疾病。大多数患者就诊时已处于疾病晚期,肿瘤常导致危及生命的胆道梗阻和肝脏血管受累。对这些肿瘤进行局部控制(LC)有可能延长患者的生命。虽然高剂量放射治疗(EDRT)已被证明是实现IHCC局部控制的一种有效、安全的选择,但关于EHCC的数据表明,采用当前技术的EDRT存在局限性,这通常是由于肝外胆道系统附近存在剂量限制的肠道结构。在此,我们回顾了EDRT治疗IHCC和EHCC的结果,并指出将放疗与新型药物联合应用的潜在方向。胆管癌的分子特征尤其为EDRT靶向治疗的临床研究开辟了新途径,并可能为实现患者全身和局部控制获益指明方向。

相似文献

3
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.基于吉西他滨的晚期胆管癌化疗
Cochrane Database Syst Rev. 2018 Apr 6;4(4):CD011746. doi: 10.1002/14651858.CD011746.pub2.
4
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.可切除胆管癌的术后辅助化疗。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD012814. doi: 10.1002/14651858.CD012814.pub2.
6
Current therapy of hilar cholangiocarcinoma.肝门部胆管癌的当前治疗方法。
Hepatobiliary Pancreat Dis Int. 2012 Feb;11(1):12-7. doi: 10.1016/s1499-3872(11)60119-7.

引用本文的文献

3
Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions.肝靶向治疗联合全身治疗:现状与未来方向
Semin Intervent Radiol. 2024 Jan 24;40(6):515-523. doi: 10.1055/s-0043-1777711. eCollection 2023 Dec.
8
Non-surgical treatment of hilar cholangiocarcinoma.肝门部胆管癌的非手术治疗
World J Gastrointest Oncol. 2021 Nov 15;13(11):1696-1708. doi: 10.4251/wjgo.v13.i11.1696.
9
Radiation therapy for recurrent extrahepatic bile duct cancer.放射性治疗复发性肝外胆管癌。
PLoS One. 2021 Jun 16;16(6):e0253285. doi: 10.1371/journal.pone.0253285. eCollection 2021.

本文引用的文献

4
Radiation-Induced Liver Disease and Modern Radiotherapy.放射性肝损伤与现代放疗
Semin Radiat Oncol. 2018 Oct;28(4):321-331. doi: 10.1016/j.semradonc.2018.06.007.
8
Wild-type and mutated IDH1/2 enzymes and therapy responses.野生型和突变型 IDH1/2 酶及治疗反应。
Oncogene. 2018 Apr;37(15):1949-1960. doi: 10.1038/s41388-017-0077-z. Epub 2018 Jan 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验